TY - JOUR
T1 - Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms Tumors
AU - van Belzen, Ianthe A.E.M.
AU - van Tuil, Marc
AU - Badloe, Shashi
AU - Strengman, Eric
AU - Janse, Alex
AU - Verwiel, Eugène T.P.
AU - van der Leest, Douwe F.M.
AU - de Vos, Sam
AU - Baker-Hernandez, John
AU - Groenendijk, Alissa
AU - de Krijger, Ronald
AU - Kerstens, Hindrik H.D.
AU - Drost, Jarno
AU - van den Heuvel-Eibrink, Marry M.
AU - Tops, Bastiaan B.J.
AU - Holstege, Frank C.P.
AU - Kemmeren, Patrick
AU - Hehir-Kwa, Jayne Y.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - Chromosomal alterations have recurrently been identified in Wilms tumors (WTs) and some are associated with poor prognosis. Gain of 1q (1q+) is of special interest given its high prevalence and is currently actively studied for its prognostic value. However, the underlying mutational mechanisms and functional effects remain unknown. In a national unbiased cohort of 30 primary WTs, we integrated somatic SNVs, CNs and SVs with expression data and distinguished four clusters characterized by affected biological processes: muscle differentiation, immune system, kidney development and proliferation. Combined genome-wide CN and SV profiles showed that tumors profoundly differ in both their types of 1q+ and genomic stability and can be grouped into WTs with co-occurring 1p−/1q+, multiple chromosomal gains or CN neutral tumors. We identified 1q+ in eight tumors that differ in mutational mechanisms, subsequent rearrangements and genomic contexts. Moreover, 1q+ tumors were present in all four expression clusters reflecting activation of various biological processes, and individual tumors overexpress different genes on 1q. In conclusion, by integrating CNs, SVs and gene expression, we identified subgroups of 1q+ tumors reflecting differences in the functional effect of 1q gain, indicating that expression data is likely needed for further risk stratification of 1q+ WTs.
AB - Chromosomal alterations have recurrently been identified in Wilms tumors (WTs) and some are associated with poor prognosis. Gain of 1q (1q+) is of special interest given its high prevalence and is currently actively studied for its prognostic value. However, the underlying mutational mechanisms and functional effects remain unknown. In a national unbiased cohort of 30 primary WTs, we integrated somatic SNVs, CNs and SVs with expression data and distinguished four clusters characterized by affected biological processes: muscle differentiation, immune system, kidney development and proliferation. Combined genome-wide CN and SV profiles showed that tumors profoundly differ in both their types of 1q+ and genomic stability and can be grouped into WTs with co-occurring 1p−/1q+, multiple chromosomal gains or CN neutral tumors. We identified 1q+ in eight tumors that differ in mutational mechanisms, subsequent rearrangements and genomic contexts. Moreover, 1q+ tumors were present in all four expression clusters reflecting activation of various biological processes, and individual tumors overexpress different genes on 1q. In conclusion, by integrating CNs, SVs and gene expression, we identified subgroups of 1q+ tumors reflecting differences in the functional effect of 1q gain, indicating that expression data is likely needed for further risk stratification of 1q+ WTs.
KW - 1q gain
KW - cancer genomics
KW - chromosomal alterations
KW - pediatric cancer
KW - RNA-seq
KW - structural variation
KW - WGS
KW - Wilms tumor
UR - http://www.scopus.com/inward/record.url?scp=85139970674&partnerID=8YFLogxK
U2 - 10.3390/cancers14194872
DO - 10.3390/cancers14194872
M3 - Article
C2 - 36230794
AN - SCOPUS:85139970674
VL - 14
JO - Cancers
JF - Cancers
IS - 19
M1 - 4872
ER -